natgillin/translations-raw huggingface dataset:
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.
Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
Film coat: hypromellose titanium dioxide (E171) lactose triacetin indigo carmine aluminium lake (E132)
Filmska obloga: hipromeloza titanov dioksid (E171) laktoza triacetin indigotin (E132)
PVC/ Aluminium foil blisters in cartons of 2, 4, 8 or 12 tablets.
Pretisni omoti iz PVC/ aluminijske folije v škatlicah po 2, 4, 8 ali 12 tablet.
No special requirements.
11 Ni posebnih zahtev.
14 September 1998 Date of last renewal:
14. september 1998 Datum zadnjega podaljšanja dovoljenja za promet:
26 August 2008
26. avgust 2008
Each tablet contains 50 mg of sildenafil (as citrate) Excipient:
Ena tableta vsebuje 50 mg sildenafila v obliki sildenafilijevega citrata.
Lactose.
Pomožna snov: laktoza.
Blue, rounded diamond-shaped tablets, marked “ PFIZER ” on one side and “ VGR 50 ” on the other.
Tablete so modre barve, imajo obliko romba z zaobljenimi robovi ter oznako "PFIZER" na eni in "VGR 50" na drugi strani.
Use in patients with impaired hepatic function:
13 Uporaba pri bolnikih z okvarjenim delovanjem jeter:
13 Use in children and adolescents:
Uporaba pri otrocih in mladostnikih:
Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of VIAGRA.
V obdobju trženja so bili v časovni povezanosti z uporabo zdravila VIAGRA opisani resni kardiovaskularni dogodki, med drugim miokardni infarkt, nestabilna angina pektoris, nenadna srčna
14 after the use of VIAGRA without sexual activity.
14 smrt, ventrikularna aritmija, cerebrovaskularna krvavitev, tranzitorna ishemična ataka, hipertenzija in hipotenzija.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the coadministration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
Previdnost je potrebna med uporabo sildenafila pri bolnikih, ki jemljejo zaviralce adrenergičnih receptorjev alfa, ker sočasna uporaba pri maloštevilnih občutljivih posameznikih lahko povzroči simptomatsko hipotenzijo (glejte poglavje 4. 5).
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC.
15 Sočasna uporaba zaviralca proteaz HIV ritonavirja, ki je zelo močan zaviralec P450, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan) in sildenafila (enkratni odmerek 100 mg) povzročila 300- odstotno (4- kratno) zvečanje Cmax sildenafila in 1, 000- odstotno (11- kratno) zvečanje AUC sildenafila v plazmi.
This is consistent with ritonavir’ s marked effects on a broad
To se sklada z izrazitimi učinki ritonavirja na številne substrate P450.
When a single 100 mg dose of sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Ob uporabi enega 100- mg odmerka sildenafila hkrati z eritromicinom, specifičnim zaviralcem CYP3A4, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan 5 dni) prišlo do 182- odstotnega zvečanja sistemske izpostavljenosti (AUC) sildenafilu.
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals.
16 Sočasna uporaba sildenafila pri bolnikih, ki jemljejo zaviralce adrenergičnih receptorjev alfa, lahko pri maloštevilnih občutljivih posameznikih povzroči simptomatsko hipotenzijo.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered
100 mg).
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, visual disorders, nasal congestion, dizziness and visual colour distortion.
Pri bolnikih zdravljenih s sildenafilom so v kliničnih študijah najpogosteje poročali o naslednjih neželenih učinkih: glavobol, zardevanje, dispepsija, motnje vida, zamašenost nosu, omotica in motnje zaznavanja barv.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period > 9 years.
17 Poročila o neželenih učinkih iz obdobja trženja pokrivajo obdobje več kot 9 let.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥ 1/ 10),
V spodnji preglednici so po organskih sistemih in pogostnosti navedeni vsi medicinsko pomembni neželeni učinki, ki so se v kliničnih preizkušanjih pojavljali pogosteje kot pri uporabi placeba.
17 common (≥ 1/ 100 to < 1/ 10), uncommon (≥ 1/ 1,000 to < 1/ 100), rare (≥ 1/ 10,000 to < 1/ 1,000).
Pogostnosti so opredeljene na naslednji način: zelo pogosti (> 1/ 10), pogosti (> 1/ 100, < 1/ 10), občasni (> 1/ 1. 000, < 1/ 100) in redki (> 1/ 10. 000, < 1/ 1. 000).
In addition, the frequency of medically important adverse reactions reported from post-marketing experience is included as not known.
Pogostnost medicinsko pomembnih neželenih učinkov, o katerih so poročali v obdobju trženja, je navedena kot neznano.
Common Uncommon
pogosto občasno Bolezni kože in podkožja
Dyspepsia Vomiting, Nausea, Dry mouth
dispepsija bruhanje, slabost, suha usta
Skin, subcutaneous and soft tissue disorders Uncommon
občasno
Musculoskeletal and connective tissue disorders Uncommon Reproductive system and breast disorders
Bolezni mišično- skeletnega sistema in vezivnega tkiva občasno Motnje reprodukcije in dojk
Not known General disorders and administration site Uncommon Investigations
neznano Splošne težave in spremembe na mestu aplikacije
Priapism, Prolonged erection conditions Chest pain, Fatigue
priapizem, dolgotrajna erekcija
Sudden deafness.
* Ušesne bolezni: nenadna oglušelost.
Sudden decrease or loss of hearing has been reported in a small number of post-marketing and clinical trials cases with the use of all PDE5 inhibitors, including sildenafil.
Med uporabo zaviralcev PDE5, vključno s sildenafilom, so v obdobju trženja in v kliničnih preskušanjih zabeležili majhno število primerov nenadnega poslabšanja sluha ali izgube sluha.
18 4.9 Overdose
4. 9 Preveliko odmerjanje
At maximum recommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7, 8, 9, 10 and 11.
V največjih priporočenih odmerkih je selektivnost 80- kratna v primerjavi s PDE1 in prek 700- kratna v primerjavi s PDE2, 3, 4, 7, 8, 9, 10 in 11.
Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation.
19 Dve klinični študiji sta bili posebej namenjeni oceni časa, v katerem lahko sildenafil po uporabi odmerka kot odziv na spolno stimulacijo povzroči erekcijo.
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil.
12 do 37 minut).
19 In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
V študiji hemodinamičnih učinkov enkratnega peroralnega 100- mg odmerka sildenafila pri 14 bolnikih s hudo boleznijo koronarnih arterij (> 70 -% stenoza vsaj ene koronarne arterije) se je srednji sistolični tlak v mirovanju v primerjavi z izhodiščem znižal za 7%, povprečni diastolični tlak v mirovanju pa za 6%.
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%).
V vseh študijah skupaj so bili deleži bolnikov, ki so s sildenafilom navajali izboljšanje, naslednji: psihogena erektilna disfunkcija (84%), mešana erektilna disfunkcija (77%), organska erektilna disfunkcija (68%), starostniki (67%), sladkorna bolezen (59%), ishemična bolezen srca (69%), zvišan krvni tlak (68%), transuretralna resekcija prostate (61%), radikalna prostatektomija (43%),
20 Distribution:
Porazdelitev:
Hepatic insufficiency:
21 Jetrna insuficienca:
PVC/ Aluminium foil blisters in cartons or secondary heat sealed card packaging of 2, 4, 8 or 12 tablets.
Pretisni omoti iz PVC/ aluminijske folije v škatlicah ali v sekundarnem, toplotno zavarjenem pakiranju po 2, 4, 8 ali 12 tablet.
Each tablet contains 100 mg of sildenafil (as citrate) Excipient:
Ena tableta vsebuje 100 mg sildenafila v obliki sildenafilijevega citrata.
Blue, rounded diamond-shaped tablets, marked “ PFIZER ” on one side and “ VGR 100 ” on the other.
Tablete so modre barve, imajo obliko romba z zaobljenimi robovi ter oznako "PFIZER" na eni in "VGR 100" na drugi strani.
Use in patients with impaired hepatic function:
24 Uporaba pri bolnikih z okvarjenim delovanjem jeter:
24 Use in children and adolescents:
Uporaba pri otrocih in mladostnikih:
With the exception of ritonavir for which co-administration with sildenafil is not advised (see section 4.4) a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5)
Pri bolnikih, ki sočasno dobivajo zaviralce CYP3A4, je priporočljivi začetni odmerek 25 mg (glejte poglavje 4. 5) razen pri ritonavirju, katerega sočasna uporaba s sildenafilom ni priporočljiva (glejte poglavje 4. 4).
Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of VIAGRA.
25 V obdobju trženja so bili v časovni povezanosti z uporabo zdravila VIAGRA opisani resni kardiovaskularni dogodki, med drugim miokardni infarkt, nestabilna angina pektoris, nenadna srčna smrt, ventrikularna aritmija, cerebrovaskularna krvavitev, tranzitorna ishemična ataka, hipertenzija in hipotenzija.
Many events were
Večina teh bolnikov, ne pa vsi, je imela že prej obstoječe kardiovaskularne dejavnike tveganja.
25 reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of VIAGRA without sexual activity.
Za številne dogodke je bilo opisano, da so se zgodili med ali kmalu po spolnem odnosu, nekateri pa so se pojavili kmalu po uporabi zdravila VIAGRA, brez spolne dejavnosti.
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mgtwice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC.
26 Sočasna uporaba zaviralca proteaz HIV ritonavirja, ki je zelo močan zaviralec P450, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan) in sildenafila (enkratni odmerek 100 mg) povzročila 300- odstotno (4- kratno) zvečanje Cmax sildenafila in 1, 000- odstotno (11- kratno) zvečanje AUC sildenafila v plazmi.
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/ ml, compared to approximately 5 ng/ ml
Po 24 urah je bila koncentracija sildenafila v plazmi še vedno približno 200 ng/ ml v primerjavi s približno 5 ng/ ml v primeru, ko je bil sildenafil apliciran sam.
Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals.
Sočasna uporaba sildenafila pri bolnikih, ki jemljejo zaviralce adrenergičnih receptorjev alfa, lahko pri maloštevilnih občutljivih posameznikih povzroči simptomatsko hipotenzijo.
27 alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
V treh specifičnih študijah interakcij med zdravili so bolnikom z benigno hiperplazijo prostate (BPH), pri katerih bolezen ni napredovala pri zdravljenju z doksazosinom, dali zaviralec adrenergičnih receptorjev alfa doksazosin (4 mg in 8 mg) sočasno s sildenafilom (25 mg, 50 mg oz.
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section(see section 5.1).
To dodatno znižanje krvnega tlaka je bilo po velikosti podobno kot pri dajanju sildenafila samega zdravim prostovoljcem (glejte poglavje 5. 1).
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, visual disorders, nasal congestion, dizziness and visual colour distortion.
28 kliničnih študijah najpogosteje poročali o naslednjih neželenih učinkih: glavobol, zardevanje, dispepsija, motnje vida, zamašenost nosu, omotica in motnje zaznavanja barv.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period > 9 years.
Poročila o neželenih učinkih iz obdobja trženja pokrivajo obdobje več kot 9 let.
28 In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥ 1/ 10), common (≥ 1/ 100 to < 1/ 10), uncommon (≥ 1/ 1,000 to < 1/ 100), rare (≥ 1/ 10,000 to < 1/ 1,000).
Pogostnosti so opredeljene na naslednji način: zelo pogosti (> 1/ 10), pogosti (> 1/ 100, < 1/ 10), občasni (> 1/ 1. 000, < 1/ 100) in redki (> 1/ 10. 000, < 1/ 1. 000).
Common Uncommon
29 pogosto občasno Bolezni kože in podkožja
Skin, subcutaneous and soft tissue disorders Uncommon
občasno Bolezni mišično- skeletnega sistema in vezivnega občasno Motnje reprodukcije in dojk
Skin rash
kožni izpuščaj tkiva mialgija
Musculoskeletal and connective tissue disorders Uncommon Reproductive system and breast disorders
neznano Splošne težave in spremembe na mestu aplikacije
Myalgia
priapizem, dolgotrajna erekcija
Not known General disorders and administration site Uncommon Not known Investigations
občasno Preiskave
Priapism, Prolonged erection conditions Chest pain, Fatigue
bolečine v prsih, utrujenost
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.
30 PDE5 kakor za PDE3 – za cAMP specifično izoobliko fosfodiesteraze, ki sodeluje pri nadzoru krčljivosti srca.
30 vasodilatory effects of sildenafil, probably due to increased cGMP levels in vascular smooth muscle.
To znižanje krvnega tlaka je skladno z vazodilatacijskimi učinki sildenafila in je verjetno posledica zvišanja ravni cGMP v žilnem gladkem mišičju.
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%).
31 V vseh študijah skupaj so bili deleži bolnikov, ki so s sildenafilom navajali izboljšanje, naslednji: psihogena erektilna disfunkcija (84%), mešana erektilna disfunkcija (77%), organska erektilna disfunkcija (68%), starostniki (67%), sladkorna bolezen (59%), ishemična bolezen srca (69%), zvišan krvni tlak (68%), transuretralna resekcija prostate (61%), radikalna prostatektomija (43%), poškodba hrbtenjače (83%), depresija (75%).
31 Distribution:
Porazdelitev:
Hypromellose titanium dioxide (E171) lactose triacetin indigo carmine aluminium lake (E132)
Filmska obloga: hipromeloza titanov dioksid (E171) laktoza triacetin indigotin (E132)
No special requirements.
33 Ni posebnih zahtev.
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
IMETNIK( I) DOVOLJENJA ZA IZDELAVO, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
35 A IMETNIK( I) DOVOLJENJA ZA IZDELAVO, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Pfizer PGM Zone Industrielle, 29 route des Industries 37530 Pocé-sur-Cisse France
Pfizer PGM Zone Industrielle, 29 route des Industries 37530 Pocé- sur- Cisse Francija
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
• POGOJI ALI OMEJITVE GLEDE IZDAJANJA IN UPORABE, KI SO NALOŽENI IMETNIKU DOVOLJENJA ZA PROMET Z ZDRAVILOM
38 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER PACKAGING / CARTON
38 PODATKI NA ZUNANJI OVOJNINI
25 mg sildenafil (as citrate)
25 mg sildenafila (v obliki sildenafilijevega citrata)
(2 film-coated tablets) (4 film-coated tablets) (8 film-coated tablets) (12 film-coated tablets)
(2 filmsko obloženi tableti) (4 filmsko obložene tablete) (8 filmsko obloženih tablet) (12 filmsko obloženih tablet)
OUTER PACKAGING / CARTON
ZUNANJA OVOJNINA/ ŠKATLA
50 mg sildenafil (as citrate)
50 mg sildenafila (v obliki sildenafilijevega citrata)
Contains lactose See package leaflet for further information
Za dodatne informacije glejte priloženo navodilo.
OUTER PACKAGING / SECONDARY HEAT SEALED CARD PACKAGING
ZUNANJA OVOJNINA/ TOPLOTNO ZAVARJENO PAKIRANJE
100 mg sildenafil (as citrate)
100 mg sildenafila (v obliki sildenafilijevega citrata)
PRIMARY PACKAGING/ BLISTER
PRIMARNA OVOJNINA/ PRETISNI OMOT
VIAGRA 100 mg film coated tablets Sildenafil
VIAGRA 100 mg filmsko obložene tablete sildenafil
INFORMATION FOR THE USER
50 NAVODILO ZA UPORABO
VIAGRA 25 mg film-coated tablets Sildenafil citrate
VIAGRA 25 mg filmsko obložene tablete sildenafilijev citrat
It may harm them, even if their symptoms are the same as yours. − If any of the side effects get serious, or you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim. − Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
What VIAGRA is and what it is used for 2.
Kaj je zdravilo VIAGRA in za kaj ga uporabljamo 2.
Before you take VIAGRA 3.
Kaj morate vedeti, preden boste vzeli zdravilo VIAGRA 3.
How to take VIAGRA 4.
Kako jemati zdravilo VIAGRA 4.
How to store VIAGRA 6.
Shranjevanje zdravila VIAGRA 6.
WHAT VIAGRA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO VIAGRA IN ZA KAJ GA UPORABLJAMO
VIAGRA belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilo VIAGRA sodi med zdravila, ki jih imenujemo zaviralci fosfodiesteraze tipa 5 (PDE5).
VIAGRA is a treatment for men with erectile dysfunction, sometimes known as impotence.
Zdravilo VIAGRA je zdravilo za moške z erektilno disfunkcijo, znano tudi kot impotenca.
BEFORE YOU TAKE VIAGRA
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO VIAGRA
− If you are taking medicines called nitrates, as the combination may cause a potentially dangerous decrease in your blood pressure.
Če jemljete zdravila, ki se imenujejo nitrati, ker lahko sočasno jemanje povzroči potencialno − nevaren padec vašega krvnega tlaka.
Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or “ chest pain”).
Povejte vašemu zdravniku, če jemljete katero od teh zdravil, ki se pogosto uporabljajo za lajšanje angine pektoris (bolečine v prsnem košu).
− If you are using any of the drugs known as nitric oxide donors such as amyl nitrite (“ poppers”), as the combination may also lead to a potentially dangerous decrease in your blood pressure.
Če jemljete zdravila, ki so znana kot dajalci dušikovega oksida, kakršen je amilnitrit (“ poppers “ − – nelegalno spolno poživilo), ker lahko sočasno jemanje povzroči potencialno nevaren padec vašega krvnega tlaka.
− If you are allergic (hypersensitive) to sildenafil or any of the other ingredients of VIAGRA.
Če ste alergični na (preobčutljivi za) sildenafil ali katerokoli sestavino zdravila VIAGRA. −
− If you have a severe heart or liver problem.
Če imate hude težave s srcem ali jetri. −
− If you have recently had a stroke or a heart attack, or if you have low blood pressure.
Če ste nedavno doživeli možgansko kap ali srčni infarkt ali če imate nizek krvni tlak. −
− If you have certain rare inherited eye diseases (such as retinitis pigmentosa).
Če imate določene redke dedne očesne bolezni (npr. retinitis pigmentosa). −
51 − If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy (NAION).
51 Če ste kadarkoli izgubili vid zaradi nearteritične anteriorne ishemične optične nevropatije − (NAION).
Take special care with VIAGRA
Bodite posebno pozorni pri jemanju zdravila VIAGRA
Tell your doctor − If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).
Povejte zdravniku Če imate srpastocelično anemijo (nepravilnost rdečih krvnih celic), levkemijo (rak krvnih celic), − multipli mielom (rak kostnega mozga).
− If you have a deformity of your penis or Peyronie’ s Disease.
Če imate deformacijo spolnega uda ali Peyroniejevo bolezen. −
− If you have problems with your heart.
Če imate težave s srcem.
Your doctor should in that case carefully check whether your heart can take the additional strain of having sex.
Zdravnik mora v tem primeru natančno preveriti, ali vaše srce lahko − prenese dodatni napor, ki je povezan s spolnimi odnosi.
− If you currently have a stomach ulcer, or a bleeding problems (such as haemophilia).
Če imate trenutno razjedo na želodcu ali če imate težave, povezane s krvavitvami (npr. − hemofilijo).
− If you experience sudden decrease or loss of vision, stop taking VIAGRA and contact your doctor immediately.
Če doživite nenadno poslabšanje ali izgubo vida, prenehajte jemati zdravilo VIAGRA in se − takoj obrnite na svojega zdravnika.
Special considerations for children and adolescents VIAGRA should not be given to individuals under the age of 18.
Posebna navodila za otroke in mladostnike Posamezniki do 18. leta starosti ne smejo dobiti zdravila VIAGRA.
Please tell your doctor or pharmacist if you are taking or have recently taken other medicines, including medicines obtained without prescription.
Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
In the event of a medical emergency, you should tell any health care professional treating your condition that you have taken VIAGRA and when you did.
V primeru nujne zdravstvene obravnave morate zdravstvenemu osebju, ki vas zdravi, povedati, da ste vzeli zdravilo VIAGRA in kdaj ste ga vzeli.
Do not take VIAGRA with other medicines unless your doctor tells you that you can.
Zdravila VIAGRA ne uporabljajte skupaj z drugimi zdravili, dokler vam zdravnik ne pove, da ga lahko.
You should not take VIAGRA if you are taking medicines called nitrates, as the combination of these products may cause a potentially dangerous decrease in your blood pressure.
Zdravila VIAGRA ne smete jemati, če jemljete zdravila, ki jih imenujemo nitrati, ker lahko sočasno jemanje teh zdravil povzroči potencialno nevaren padec vašega krvnega pritiska.